Alembic receives USFDA final approval for Paliperidone ER tablets
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Also received tentative approval for 137 mg
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Subscribe To Our Newsletter & Stay Updated